HC Wainwright Analysts Decrease Earnings Estimates for AVDL

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for Avadel Pharmaceuticals in a note issued to investors on Tuesday, March 4th. HC Wainwright analyst O. Livnat now forecasts that the company will post earnings of ($0.06) per share for the quarter, down from their prior forecast of ($0.05). HC Wainwright has a “Buy” rating and a $21.00 price objective on the stock. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Avadel Pharmaceuticals’ FY2025 earnings at ($0.03) EPS, FY2026 earnings at $0.84 EPS, FY2027 earnings at $1.44 EPS, FY2028 earnings at $1.54 EPS and FY2029 earnings at $1.83 EPS.

AVDL has been the topic of several other reports. UBS Group reduced their price target on Avadel Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating on the stock in a report on Monday, January 13th. Needham & Company LLC restated a “buy” rating and set a $19.00 price target on shares of Avadel Pharmaceuticals in a report on Monday, March 3rd. Piper Sandler reduced their price target on Avadel Pharmaceuticals from $24.00 to $13.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Finally, Deutsche Bank Aktiengesellschaft began coverage on Avadel Pharmaceuticals in a report on Tuesday, February 11th. They set a “buy” rating and a $12.00 price target on the stock. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $19.88.

Avadel Pharmaceuticals Trading Up 0.4 %

NASDAQ:AVDL opened at $7.91 on Friday. The stock has a market cap of $762.22 million, a P/E ratio of -10.01 and a beta of 1.28. The stock’s 50-day moving average is $8.62 and its 200-day moving average is $11.43. Avadel Pharmaceuticals has a 1-year low of $7.39 and a 1-year high of $19.09.

Hedge Funds Weigh In On Avadel Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in AVDL. Creative Planning lifted its stake in Avadel Pharmaceuticals by 8.2% in the third quarter. Creative Planning now owns 12,381 shares of the company’s stock valued at $162,000 after buying an additional 938 shares during the period. Crossmark Global Holdings Inc. acquired a new position in Avadel Pharmaceuticals in the third quarter valued at approximately $350,000. Aigen Investment Management LP acquired a new position in Avadel Pharmaceuticals in the third quarter valued at approximately $160,000. Oppenheimer & Co. Inc. raised its position in shares of Avadel Pharmaceuticals by 9.2% during the third quarter. Oppenheimer & Co. Inc. now owns 33,105 shares of the company’s stock worth $434,000 after purchasing an additional 2,780 shares during the period. Finally, MAI Capital Management raised its position in shares of Avadel Pharmaceuticals by 1.0% during the third quarter. MAI Capital Management now owns 107,533 shares of the company’s stock worth $1,410,000 after purchasing an additional 1,031 shares during the period. 69.19% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Avadel Pharmaceuticals

In other Avadel Pharmaceuticals news, Director Geoffrey Michael Glass purchased 20,279 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were purchased at an average cost of $9.84 per share, with a total value of $199,545.36. Following the completion of the purchase, the director now owns 75,904 shares in the company, valued at $746,895.36. This represents a 36.46 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Linda Palczuk purchased 5,000 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was acquired at an average cost of $7.93 per share, for a total transaction of $39,650.00. Following the completion of the purchase, the director now owns 67,900 shares of the company’s stock, valued at approximately $538,447. This trade represents a 7.95 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 42,981 shares of company stock worth $400,005 over the last ninety days. Insiders own 4.80% of the company’s stock.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.